Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 12/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586883 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL18575668 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13030857 | 1.00 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13145227 | 0.86 | CDA (0.75) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL14931007 | 0.80 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13030835 | 0.79 | CDA (0.65) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL23227176 | 0.78 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL20788791 | 0.78 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL23467212 | 0.78 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL171923 | 0.78 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416780-B1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416781-B1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416780-B1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416781-B1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2417146-B1 | (2'-DEOXY-RIBOFURANOSYL)-1,3,4,7-TETRAHYDRO-(1,3)DIAZEPIN-2-ONE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| EP-2417146-B1 | (2'-DEOXY-RIBOFURANOSYL)-1,3,4,7-TETRAHYDRO-(1,3)DIAZEPIN-2-ONE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010118006-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118006-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118010-A1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118010-A1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118013-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118013-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNG, DUT, DCTD | CDA 49/4885PDE4D 1128/4885PDE3A 656/4885 |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.